About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars, recently spun off from Novartis into an independent entity.
Milestones
Milestones as listed on sandoz.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sandoz.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on sandoz.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Generic medicines
Part of a global portfolio of about 1,300 generic and biosimilar medicines.
Source: sandoz.comBiosimilars
13 marketed biosimilars in areas including oncology, immunology, neurology, ophthalmology, endocrinology and nephrology.
Source: sandoz.comOmnitrope (somatropin)
Launched in 2006; Sandoz describes it as the world's first biosimilar medicine.
Source: sandoz.comBiosimilar pipeline
Up to 39 biosimilar candidates at various stages of development.
Source: sandoz.comPipeline & Regulatory Record
What public registers list for Sandoz: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.
Clinical trials 2 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis NCT06847724 · Relapsing Multiple Sclerosis |
Phase 3 | Active, closed |
| Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting NCT05633771 · Inflammatory Bowel Disease |
Observational | Active, closed |
Drugs in these trials 1 compounds
Recent approvals
- BysumlogEMA · insulin lispro · 6 May 2026 · biosimilar
- OndibtaEMA · insulin glargine · 9 Jan 2026 · biosimilar
- FidaxomicinFDA · Fidaxomicin · 13 Aug 2026 · Generic (ANDA)
- TigecyclineFDA · Tigecycline · 27 May 2015 · Generic (ANDA)
- DurezolFDA · Difluprednate · 23 Jun 2008 · New Drug (NDA)
Medicine shortages 7 in the FDA list
- Clindamycin Phosphate InjectionUS (FDA) · in shortage · updated 21 Sep 2026
- Oxaliplatin InjectionUS (FDA) · resolved · updated 29 Jun 2026
- Fluvastatin Sodium Tablet, Extended ReleaseUS (FDA) · resolved · updated 27 Jan 2026
- Adalimumab-adaz InjectionUS (FDA) · resolved · updated 13 Jan 2026
- Ampicillin Sodium InjectionUS (FDA) · resolved · updated 8 Dec 2025
- Pemetrexed Disodium InjectionUS (FDA) · resolved · updated 16 Oct 2025
- Omeprazole Delayed Release CapsuleUS (FDA) · resolved · updated 9 Oct 2025
A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.
NICE technology appraisals 1 of its medicines · 1 current
- Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyNICE TA1126 · Optimised, Not recommended · 28 Jan 2026
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
How this is matched: register records are linked to this page by the organisation name they carry, here Sandoz; Sandoz Pharmaceuticals d.d.; Sandoz GmbH; Sandoz Pharmaceuticals GmbH; SANDOZ; Sandoz Inc.. Spot a wrong match? Tell us.